Distribution of the Components of the NCEP ATP III-defined Metabolic Syndrome in Newly Diagnosed Diabetes and Non-diabetes Caucasian Subjects; Implications for Metabolic Syndrome Prevention and Treatment

 

 Buy Article Permissions and Reprints

Abstract

The study aimed at assessing the relationship between five components of the NCEP ATPIII-defined metabolic syndrome (MS) in diabetes and non-diabetes MS subjects.

Methods: Prevalence of MS and its components was assessed in 1586 adult Caucasian individuals, without known diabetes. Oral glucose tolerance test (OGTT) with 75 g glucose according to WHO protocol was conducted in all subjects.

Results: MS was diagnosed in 419 persons (prevalence 26.4%), including 123 subjects with newly diagnosed diabetes. Diabetes subjects presented with higher plasma triglycerides and slightly more pronounced abdominal obesity as well as higher fasting plasma insulin, which in all reflected insulin resistance-related character of MS pathophysiology. However, the distribution of MS components was largely uneven in diabetes and non-diabetes subjects. Elevated plasma triglycerides and low HDL cholesterol were the most prevalent components. The least often found component was elevated fasting plasma glucose (FPG). Non-diabetes subjects with elevated FPG were more likely to present with three or four other components than with two of them only. In contrast, those with high plasma triglycerides, low plasma HDL cholesterol or increased waist circumference were all more likely to have two rather than three or four other MS components. Subjects with diabetes presented significantly more often with four or five MS components when compared with non-diabetes subjects.

Conclusions: The components of metabolic syndrome are not equally prevalent in Caucasian population. Lipid disorders are most often found and glucose intolerance is the least prevalent MS component. Glucose intolerance and diabetes occurred in a more complex setting, concomitantly with three or four other MS components, suggesting that diabetes is associated with more advanced stages of MS. These findings may have important implications for MS prevention and treatment.

References

• 1 Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older.  Diabetes. 2003;  52 1210-1214
  CrossrefPubMedGoogle Scholar
• 2 Anderson JL, Horne BD, Jones HU, Reyna SP, Carlquist JF, Bair TL, Pearson RR, Lappe DL, Muhlestein JB. Intermountain Heart Collaboration (IHC) Study . Which Features of the Metabolic Syndrome Predict the Prevalence and Clinical Outcomes of Angiographic Coronary Artery Disease?.  Cardiology. 2004;  101 185-193
  CrossrefPubMedGoogle Scholar
• 3 Central Statistical Office, Poland . 2004;  ,  http://www.stat.gov.pl/english/index.htm accessed 15 July 2006
• 4 Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to Insulin Resistance of the Adult Treatment Panel III Diagnostic Criteria for Identification of the Metabolic Syndrome.  Diabetes. 2004;  53 1195-1200
  CrossrefPubMedGoogle Scholar
• 5 Diabetes Atherosclerosis Intervention Study Investigators . Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.  Lancet. 2001;  357 905-910
  CrossrefPubMedGoogle Scholar
• 6 Drzewoski J, Saryusz-Wolska M, Czupryniak L. Prevalence of type 2 diabetes mellitus and selected metabolic disorders in urban population aged >35 years.  Pol Arch Med Wewn. 2001;  106 787-791
  PubMedGoogle Scholar
• 7 Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults . Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
  CrossrefPubMedGoogle Scholar
• 8 Ford ES, Giles WH, Dietz WH. Prevalence of the Metabolic Syndrome Among US Adults. Findings From the Third National Health and Nutrition Examination Survey.  JAMA. 2002;  287 356-359
  CrossrefPubMedGoogle Scholar
• 9 Hanefeld M, Leonhardt W. Das Metabolische Syndrome.  Dtsch Gesundheitsw. 1981;  36 545-551
  PubMedGoogle Scholar
• 10 Hanley AJG, Wagenknecht LE, D'Agostino Jr RB, Zinman B, Haffner SM. Identification of Subjects with Insulin Resistance and β-Cell Dysfunction Using Alternative Definitions of the Metabolic Syndrome.  Diabetes. 2003;  52 2740-2747
  CrossrefPubMedGoogle Scholar
• 11 Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group. Prevalence of the Metabolic Syndrome and Its Relation to All-Cause and Cardiovascular Mortality in Nondiabetic European Men and Women.  Arch Intern Med. 2004;  164 1066-1076
  CrossrefPubMedGoogle Scholar
• 12 Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L. Cardiovascular morbidity and mortality associated with the metabolic syndrome.  Diabetes Care. 2001;  24 683-689
  CrossrefPubMedGoogle Scholar
• 13 Jacobson TA, Case CC, Roberts S, Buckley A, Murtaugh KM, Sung JCY, Gause D, Varas C, Ballantyne CM. Characteristics of US adults with the metabolic syndrome and therapeutic implications.  Diabetes Obesity Metabol. 2004;  6 353-362
  PubMedGoogle Scholar
• 14 Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT. The Metabolic Syndrome and Total and Cardiovascular Disease Mortality in Middle-aged Men.  JAMA. 2002;  288 2709-2716
  CrossrefPubMedGoogle Scholar
• 15 Linnemann B, Voigt W, Nobel W, Janka HU. C-reactive protein is a strong independent predictor of death in type 2 diabetes: association with multiple facets of the metabolic syndrome.  Exp Clin Endocrinol Diabetes. 2006;  114 127-134
  Article in Thieme ConnectPubMedGoogle Scholar
• 16 Lorenzo C, Okoloise M, Williams K, Stern MP, Haffner SM. The Metabolic Syndrome as Predictor of Type 2 Diabetes. The San Antonio Heart Study.  Diabetes Care. 2003;  26 3153-3159
  CrossrefPubMedGoogle Scholar
• 17 Matsuzawa Y. The metabolic syndrome and adipocytokines.  FEBS Lett. 2006;  580 2917-2921
  CrossrefPubMedGoogle Scholar
• 18 Meigs JB, Wilson PWF, Nathan DM, D’Agostino Sr RB, Williams K, Haffner SM. Prevalence and Characteristics of the Metabolic Syndrome in the San Antonio Heart and Framingham Offspring Studies.  Diabetes. 2003;  52 2160-2167
  PubMedGoogle Scholar
• 19 Meigs JB. Insulin Resistance Syndrome? Syndrome X? Multiple Metabolic Syndrome? A Syndrome At All? Factor Analysis Reveals Patterns in the Fabric of Correlated Metabolic Risk Factors.  Am J Epidemiol. 2000;  152 908-911
  CrossrefPubMedGoogle Scholar
• 20 Mielck A, Reitmeir P, Rathmann W. Knowledge about diabetes and participation in diabetes training courses: the need for improving health care for diabetes patients with low SES.  Exp Clin Endocrinol Diabetes. 2006;  114 240-248
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 Mori Y, Hoshino K, Yokota K, Yokose T, Tajima N. Increased visceral fat and impaired glucose tolerance predict the increased risk of metabolic syndrome in Japanese middle-aged men.  Exp Clin Endocrinol Diabetes. 2005;  113 334-339
  Article in Thieme ConnectPubMedGoogle Scholar
• 22 Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FLJ, SMART Study Group. The Metabolic Syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm.  Eur Heart J. 2004;  25 342-348
  CrossrefPubMedGoogle Scholar
• 23 Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB. The Metabolic Syndrome. Prevalence and Associated Risk Factor Findings in the US Population From the Third National Health and Nutrition Examination Survey 1998-1994.  Arch Intern Med. 2003;  163 427-436
  CrossrefPubMedGoogle Scholar
• 24 Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease.  Diabetes. 1998;  37 1595-1607
  CrossrefPubMedGoogle Scholar
• 25 Stumvoll M, Gerich J. Clinical features of insulin resistance and beta cell dysfunction and the relationship to type 2 diabetes.  Clin Lab Med. 2001;  21 31-51
  PubMedGoogle Scholar
• 26 Szybinski Z. Polish Multicenter Study on Diabetes Epidemiology 1998-2000.  Pol Arch Med Wewn. 2001;  106 751-758
  PubMedGoogle Scholar
• 27 Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V. Uusitupa M; Finnish Diabetes Prevention Study Group . Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance.  N Engl J Med. 2001;  344 1343-1350
  CrossrefPubMedGoogle Scholar
• 28 Turner RC, Matthews DR, Holman RR, Peto J. Relative contributions of insulin deficiency and insulin resistance in maturity-onset diabetes.  Lancet. 1982;  i 596-598
  CrossrefPubMedGoogle Scholar
• 29 WHO Consultation .Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organization 1999
  Google Scholar

1 The paper was presented in part as an abstract at the 18th International Diabetes Federation Congress in Paris, August 2003.

Correspondence

L. Czupryniak

Department of Diabetology and Metabolic Diseases

Medical University of Lodz

Barlicki University Hospital No 1

ul. Kopcinskiego 22

90-153, Lodz, Poland

Phone: +48/42/677 66 66

Fax: +48/42/678 64 80

Email: bigosik@poczta.onet.pl